Denali Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

Tividenofusp alfa (DNL310; ETV:IDS) launch readiness established ahead of April 5, 2026 PDUFA target action date for Hunter syndrome

Published on Feb. 27, 2026

Got story updates? Submit your updates here. ›

Denali Therapeutics Inc. today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided business highlights. The company made progress toward delivering treatment options for neurodegenerative diseases and lysosomal storage disorders, including establishing commercial readiness for the anticipated launch of tividenofusp alfa for Hunter syndrome and advancing its TransportVehicle platform across serious diseases. Denali also presented preliminary Phase 1/2 data for DNL126 in Sanfilippo syndrome type A that support an accelerated approval path, and announced plans to initiate clinical studies of DNL628 in Alzheimer's disease and DNL952 in late-onset Pompe disease.

Why it matters

Denali's progress on its pipeline of therapies targeting neurodegenerative diseases and lysosomal storage disorders represents an important step forward in addressing unmet medical needs for patients and families affected by these serious conditions. The company's focus on innovative delivery technologies like its TransportVehicle platform could enable more effective treatments to reach the brain and other key tissues.

The details

Denali has established commercial launch readiness for tividenofusp alfa, its enzyme replacement therapy for Hunter syndrome, ahead of the April 5, 2026 PDUFA target action date. The company also presented positive preliminary data for DNL126 in Sanfilippo syndrome type A, supporting plans to pursue an accelerated approval path. Additionally, Denali announced plans to initiate clinical studies of DNL628 in Alzheimer's disease and DNL952 in late-onset Pompe disease.

  • Tividenofusp alfa has a PDUFA target action date of April 5, 2026.
  • Denali presented preliminary Phase 1/2 data for DNL126 at the 2026 WORLD Symposium.
  • Denali announced plans to initiate the Phase 1b study of DNL628 and the Phase 1 study of DNL952 in January 2026.

The players

Denali Therapeutics Inc.

A biotechnology company pioneering a new class of biotherapeutics designed to cross the blood-brain barrier using its proprietary TransportVehicle platform.

Ryan Watts, Ph.D.

Chief Executive Officer of Denali Therapeutics.

Got photos? Submit your photos here. ›

What they’re saying

“In 2025, we made meaningful progress toward delivering urgently needed treatment options for people living with neurodegenerative diseases and lysosomal storage disorders, building on the strong scientific foundation that defines Denali.”

— Ryan Watts, Chief Executive Officer (Denali Therapeutics)

“In 2026, we are focused on launching tividenofusp alfa and transforming life for individuals living with other serious diseases. Data presented at WORLD Symposium support our plans to pursue an accelerated approval path for DNL126 in Sanfilippo syndrome type A. We are also initiating clinical studies of DNL628 (OTV:MAPT) in Alzheimer's disease and DNL952 (ETV:GAA) in late-onset Pompe disease.”

— Ryan Watts, Chief Executive Officer (Denali Therapeutics)

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

Denali's progress on its pipeline of therapies targeting neurodegenerative diseases and lysosomal storage disorders represents an important step forward in addressing unmet medical needs for patients and families affected by these serious conditions. The company's focus on innovative delivery technologies could enable more effective treatments to reach the brain and other key tissues.